In summary, our finding that HR488B as a novel HDAC1 inhibitor, that remarkably repressed the growth of CRC both in vitro and in vivo without causing any significant toxicity, and further explored its molecular mechanism. Here, HDAC1 is linked to colorectal carcinoma.